Jennison Associates
NTLA icon

Jennison Associates’s Intellia Therapeutics NTLA Stock Holding History

Jennison Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,899
Closed -$984K – 622
2024
Q3 		$984K Buy
47,899
+8,497
+22% +$196K ﹤0.01% 488
2024
Q2 		$882K Buy
39,402
+5,786
+17% +$138K ﹤0.01% 498
2024
Q1 		$925K Buy
33,616
+9,768
+41% +$271K ﹤0.01% 509
2023
Q4 		$727K Buy
23,848
+4,949
+26% +$142K ﹤0.01% 526
2023
Q3 		$598K Buy
18,899
+871
+5% +$33.8K ﹤0.01% 523
2023
Q2 		$735K Buy
+18,028
New +$731K ﹤0.01% 519
2022
Q2 		– Sell
-310,036
Closed -$22.5M – 673
2022
Q1 		$22.5M Sell
310,036
-725,362
-70% -$61.5M 0.02% 337
2021
Q4 		$122M Buy
1,035,398
+116,821
+13% +$14.6M 0.08% 108
2021
Q3 		$123M Sell
918,577
-148,920
-14% -$22.5M 0.08% 103
2021
Q2 		$173M Sell
1,067,497
-72,374
-6% -$5.64M 0.11% 85
2021
Q1 		$91.5M Buy
1,139,871
+987,773
+649% +$66.3M 0.07% 125
2020
Q4 		$8.27M Buy
+152,098
New +$5.52M 0.01% 422

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates's NTLA Position: Q4 2024 in Review

Jennison Associates sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 47,899 shares — an estimated $984K sold.

Jennison Associates first reported a position in NTLA in Q4 2020 and held it in 12 quarters. The position peaked at $173M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Jennison Associates reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jennison Associates sold 47,899 Intellia Therapeutics shares in Q4 2024, an estimated $984K.
  • Jennison Associates first reported a position in Intellia Therapeutics in Q4 2020 and held it in 12 quarters.
  • Jennison Associates's Intellia Therapeutics position peaked at $173M in Q2 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Jennison Associates's 13F filing for Q4 2024, filed 24 Jan 2025.